OmniAb Inc (NAS:OABI)

Q3 2024 OmniAb Inc Earnings Call Transcript

Nov 12, 2024 / 09:30 PM GMT

Release Date Price: $4.49 (-2.39%)

Transcript 10-Q8-K

Key Points

Positve

OmniAb Inc (OABI) reported strong growth in active programs, with 39 new additions and only 12 terminations, indicating robust interest in their technology.
The company signed three new platform license agreements with notable institutions, including 92 Bio, Memorial Sloan Kettering Cancer Center, and Queen Mary University of London.
OmniAb Inc (OABI) expanded its ion channel screening relationship with Syngenta and entered a new license with Insight Corporation, showcasing successful business development efforts.
The company has a diversified base of 86 active partners, which helps mitigate risks associated with industry cycles.
OmniAb Inc (OABI) maintains a strong financial position with $59.4 million in cash, providing strategic flexibility and resilience against macroeconomic pressures.

Negative

Total revenue for the quarter decreased to $4.2 million from $5.5 million in the prior year, primarily due to lower milestone and ion channel service revenue.
The company reported a net loss of $16.4 million for the third quarter, slightly higher than the $15.7 million loss in the prior year period.
OmniAb Inc (OABI) observed industry pressures leading to restructurings and pipeline reprioritizations, which could drive additional volatility in their business.
There is a cautious outlook due to macroeconomic conditions affecting the biopharmaceutical industry, potentially impacting future revenue streams.
The company had to raise additional capital through an at-the-market security offering, indicating a need for financial cushioning amidst uncertain industry conditions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

OABI.OQ - OmniAB Inc
Q3 2024 OmniAb Inc Earnings Call
Nov 12, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Omniab Inc third quarter, 2024 financial results and business update conference call at this time, all participants are in a listen-only mode, a question and answer session will follow the formal presentation as a reminder, this conference is being recorded.

I would now like to turn the call over to Kurt Gustafson. Omniab in Chief Financial Officer. You may begin. Thank.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
You.

Thank you operator and good afternoon to everyone. This is Kurt Gustafson, Omniab's co. Thank you all for joining our third quarter

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.